Seongnam, South Korea

Young K Choi

This inventor holds 1 USPTO granted patent. Top assignee: Daewoong Pharmaceutical Co., Ltd.. Active years: 1994.


% Patents Active = 100.0

Average Co-Inventor Count = 8.0

ph-index = 1

Forward Citations = 10(Granted Patents)


Company Filing History:


Years Active: 1994

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Young K Choi: Innovator in Cephem Compounds

Introduction

Young K Choi is a notable inventor based in Seongnam, South Korea. He has made significant contributions to the field of pharmaceuticals, particularly in the development of cephem compounds. His innovative work has led to the filing of a patent that showcases his expertise and dedication to advancing medical science.

Latest Patents

Young K Choi holds a patent for "3-substituted cephem compounds." This invention represents a crucial advancement in antibiotic development, potentially offering new treatment options for various bacterial infections. The patent highlights his commitment to improving healthcare through innovative solutions.

Career Highlights

Young K Choi is currently employed at Daewoong Pharmaceutical Co., Ltd. His role at this esteemed company allows him to collaborate with other talented professionals in the pharmaceutical industry. His work has not only contributed to the company's success but has also positioned him as a key figure in the field of medicinal chemistry.

Collaborations

Young K Choi has worked alongside talented colleagues, including Chi Jang Moon and Sae C Park. Their collaborative efforts have fostered an environment of innovation and creativity, leading to significant advancements in their respective projects.

Conclusion

In summary, Young K Choi is a distinguished inventor whose work in cephem compounds has the potential to impact the pharmaceutical industry positively. His contributions, along with his collaborations, reflect a commitment to innovation and excellence in healthcare.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…